Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LU-NAR): a randomised, open-label, pivotal phase 3 study.

Leal T; Kotecha R; Ramlau R; Zhang L; Milanowski J; Cobo M; Roubec J; Petruzelka L; Havel L; Kalmadi S; Ward J; Andric Z; Berghmans T; Gerber DE; Kloecker G; Panikkar R; Aerts J; Delmonte A; Pless M; Greil R; Rolfo C; Akerley W; Eaton M; Iqbal M; Langer C.

Lancet Oncol. 2023 Sep;24(9):1002-1017. doi: 10.1016/S1470-2045(23)00344-3.

https://pubmed.ncbi.nlm.nih.gov/37657460/